Selected Protease Inhibitors/Nevirapine
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
The cause of the interaction is not known.
What might happen:
Blood levels of your protease inhibitor may decrease, causing it to become less effective, or allowing your HIV to develop resistance to your medicine.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) about taking these two medicines together. They may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Marino RT. Personal communication. Boehringer Ingelheim Pharmaceuticals, Inc. February 7, 2001.
2.Viramune (nevirapine) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. November, 2011.
3.Agenerase (amprenavir) Oral Solution US prescribing information. GlaxoSmithKline May, 2005.
4.Lexiva (fosamprenavir calcium) US prescribing information. GlaxoSmithKline February, 2013.
5.Viracept (nelfinavir mesylate) US prescribing information. Agouron Pharmaceuticals, Inc. April, 2012.
6.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. February, 2012.
7.Fortovase (saquinavir) US prescribing information. Roche Laboratories, Inc. December, 2004.
8.Crixivan (indinavir sulfate) US prescribing information. Merck & Co., Inc. February, 2011.





